Trial Profile

Imaging Tumor-infiltrating CD8+ T-cells in Non-small Cell Lung Cancer Upon Neo-adjuvant Treatment With Durvalumab (MEDI4736)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 09 Dec 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Durvalumab (Primary)
Indications Carcinoma; Non-small cell lung cancer
Focus Adverse reactions; Therapeutic Use
Acronyms Donan

Most Recent Events

06 Dec 2022 Status changed from recruiting to completed.
20 May 2022 Planned primary completion date changed from 1 Apr 2022 to 1 Jul 2022.
22 Oct 2021 Planned End Date changed from 1 Apr 2022 to 1 Oct 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com